Characteristics of HPV-Specific Antibody Responses Induced by Infection and Vaccination: Cross-Reactivity, Neutralizing Activity, Avidity and IgG Subclasses

Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis

(2012) Talía Malagón et al.   LANCET INFECTIOUS DISEASES

Seroprevalence of seven high-risk HPV types in The Netherlands

(2012) Mirte Scherpenisse et al.   VACCINE

Prevalent Serum Antibody Is Not a Marker of Immune Protection against Acquisition of Oncogenic HPV16 in Men

(2011) B. Lu et al.   CANCER RESEARCH

Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine

(2011) Francis J. Dessy et al.   Human vaccines & immunotherapeutics

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine

(2011) Mark H. Einstein et al.   Human vaccines & immunotherapeutics

Allergens and their role in the allergic immune response

(2011) Thomas A. E. Platts-Mills et al.   IMMUNOLOGICAL REVIEWS

A Competitive Serological Assay Shows Naturally Acquired Immunity to Human Papillomavirus Infections in the Guanacaste Natural History Study

(2011) Nicolas Wentzensen et al.   JOURNAL OF INFECTIOUS DISEASES

A Murine Genital-Challenge Model Is a Sensitive Measure of Protective Antibodies against Human Papillomavirus Infection

(2011) S. Longet et al.   JOURNAL OF VIROLOGY

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

(2011) Matti Lehtinen et al.   LANCET ONCOLOGY

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

(2011) Cosette M Wheeler et al.   LANCET ONCOLOGY

High Human Immunodeficiency Virus Incidence in a Cohort of Rwandan Female Sex Workers

(2011) Sarah L. Braunstein et al.   SEXUALLY TRANSMITTED DISEASES

Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera

(2011) Eve Draper et al.   VACCINE

HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection

(2011) Troy J. Kemp et al.   VACCINE

Current concepts on human papillomavirus infections in children

(2010) STINA SYRJÄNEN   APMIS

Structure and function of immunoglobulins

(2010) Harry W. Schroeder et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Epidemiological Study of Anti-HPV16/18 Seropositivity and Subsequent Risk of HPV16 and -18 Infections

(2010) M. Safaeian et al.   JNCI-Journal of the National Cancer Institute

Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes

(2010) Johanna Palmroth et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES

Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine

(2010) Joseph G. Dauner et al.   VACCINE

Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women

(2010) N. De Carvalho et al.   VACCINE

Human Papillomaviruses: Genetic Basis of Carcinogenicity

(2009) Robert D. Burk et al.   Public Health Genomics

Prevalence and Incidence of HPV Genital Infection in Women

(2009) Christine Velicer et al.   SEXUALLY TRANSMITTED DISEASES